Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Rheumatoid Arthritis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Rheumatoid Arthritis
    TopAbstracts in Rheumatoid Arthritis 11/12/2009 - (DGNews)
    Anti-TNF Treatment Does Not Increase Cancer Risk in Patients With RA - (DGNews)
    TopAbstracts in Rheumatoid Arthritis 10/29/2009 - (DGNews)
    Tocilizumab Plus Methotrexate Provides Sustained Benefits in Patients With RA: Presented at ACR/ARHP - (DGDispatch)
    Novel JAK Inhibitor Shows Promise as an Effective Treatment for Rheumatoid Arthritis: Presented at ACR/ARHP - (DGDispatch)

    News archive

     Recent webcasts/CME - Rheumatoid Arthritis
      Comorbidity in Patients with Rheumatoid Arthritis: What are the Real Concerns?
      Advances in Basic Science
      Quantitatively-Driven Management of Rheumatoid Arthritis
      Cancer, Liver, Infections, Cardiovascular Disease, and other Biologic Agents
      Rheumatoid Arthritis: Clinical Aspects, Outcomes, and Measures

      Webcasts/CME archive

       Recent cases - Rheumatoid Arthritis
        Mesenteric Rheumatoid Nodules Masquerading as an Intra-Abdominal Malignancy: A Case Report and Review of the Literature
        Co-Existence of Acute Myeloid Leukemia with Multilineage Dysplasia and Epstein-Barr Virus-Associated T-Cell Lymphoproliferative Disorder in a Patient with Rheumatoid Arthritis
        Patient with Hepatitis B and Rheumatoid Arthritis
        Complete Heart Block and Severe Aortic Stenosis in a Patient with Rheumatoid Arthtritis: A Case Report
        Limited Wegener's Granulomatosis Presenting as Lung Nodules in a Patient with Rheumatoid Arthritis: A Case Report

        Cases archive
          




        my personal edition > rheumatoid arthritis > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Infliximab Added to DMARD Therapy Keeps Patients at Work: Presented at ACR-ARHP

          By Roberta Friedman, PhD

          SAN FRANCISCO, Calif -- October 27, 2008 -- Patients with rheumatoid arthritis (RA) lose fewer work days when infliximab is added to a combination of methotrexate, sulfasalazinesulphasalazine, hydroxychloroquine, and prednisolone, according to phase 4 trial results presented here at the American College of Rheumatology (ACR) - Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting.

          The study results, from the NEO-RACo study, were reported here on October 27, by investigator Marjatta Leirisalo-Repo, MD, University Central Hospital, Helsinki, Finland.

          The study followed 100 previously -untreated patients <65 years old and who had had RA symptoms for ≤1 year or less. These patients were randomised to receive treatment with infliximab 3 mg/kg or placebo at weeks 4, 6, 10, 18, and 26 after starting the combined combination drug regimen.

          Doses of methotrexate up to ≤25 mg and sulfasalazine up to ≤2 g were used until the patient achieved disease remission was achieved.

          Dr. Leirisalo-Repo noted that the study recruited newly -diagnosed patients who were given disease-modifying antirheumatic drugs (DMARD) therapy as well as local, intra-articular steroids injections. "We aim to [induce] remission," she said.

          Patients had at least 6 swollen and at least 6 tender joints, morning stiffness for at least 45 minutes, and an erythrocyte sedimentation rate ESR of at least ≤30 mm/h or C-reactive proteinCRP of at least ≤20 mg/L.

          Half of the patients received infliximab. Patients were followed up for 2 years, and days of RA-related absence from work were recorded at each visit.

          Results at 2 years show a trend toward a higher percentage of patients having achieved RA remission according to American College of Rheumatology criteria in the infliximab arm (70%) compared with those receiving placebo (53%).

          Dr. Leirisalo-Repo said that as the trial has continued, this difference has came to achieved statistical significance.

          "Most important," she said, "work disability days are statistically significantly different between the 2 groups." Those on infliximab had 2.5 median missed days, compared with 31 days for those in the placebo arm.

          Schering-Plough Corporation donated the study drug used for this trial.


          [Presentation title: Adding Infliximab to Triple DMARD Plus Prednisolone Therapy Reduces Absence From Work in Patients With Early Active Rheumatoid Arthritis. Results From a Double-Blind Placebo-Controlled Study (NEO-RACo). Abstract number 1000]




        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send